Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection

Table 3 Unadjusted and adjusted models assessing the correlation of plasma IP-10 and MIP-1β levels (log pg/mL) with ALT and HCV RNA levels in ATAHC participants with detectable HCV RNA at the time of acute HCV detection

	Unadjusted model		Adjusted model^*
	Estimated Mean difference^** (95 % CI)	P	Estimated Mean difference^** (95 % CI)	P
IP-10 level, log pg/mL
ALT level, log IU/L	0.21 (0.13, 0.30)	<0.001	0.20 (0.07, 0.32)	0.002
HCV RNA level
<8,500 IU/mL	Reference		Reference
8,500 - 400,000 IU/mL	0.03 (−0.07, 0.14)	0.512	−0.05 (−0.17, 0.07)	0.414
>400,000 IU/mL	0.27 (0.17, 0.37)	<0.001	0.16 (0.03, 0.28)	0.014
MIP-1β level, log pg/mL
ALT level, log IU/L	0.16 (0.06, 0.26)	0.001	0.09 (−0.06, 0.24)	0.224
HCV RNA level
<8,500 IU/mL	Reference		Reference
8,500 - 400,000 IU/mL	0.14 (0.02, 0.26)	0.020	0.10 (−0.04, 0.24)	0.165
>400,000 IU/mL	0.25 (0.13, 0.37)	<0.001	0.16 (0.01, 0.31)	0.036

*Adjusted for variables associated with the outcome cytokine (i.e., IP-10 or MIP-1β), ALT or HCV RNA levels (P < 0.200) in unadjusted analysis, including sex, age, symptomatic acute HCV, estimated duration of infection, HIV co-infection, Interferon lambda rs12979860 genotype, HCV genotype, and assay run; n = 113; R² = 0.40 (for the IP-10 model); R² = 0.28 (for the MIP-1β model)
**β coefficient

ISSN: 1743-422X